



Report for the period  
1 January 2023 – 30 September 2023

---

**14<sup>th</sup> November 2023**

---

## Table of contents

1. General information about the Company.....	3
1.1 Company details.....	3
1.2 Company profile.....	3
1.3 Management Board.....	4
1.4 Shareholder structure.....	5
1.5 Persons employed.....	5
2. Condensed Standalone Financial Statements .....	6
2.1 Condensed Standalone statement of comprehensive income and financial position.....	6
2.2 Condensed Standalone statement of cashflow .....	8
2.3 Condensed Standalone statement of changes in equity.....	9
3. Condensed Consolidated Financial Statement .....	10
3.1 Condensed Consolidated Statement of comprehensive income.....	10
3.2 Condensed Statement of financial position .....	11
3.3. Condensed Consolidated Statement of cash flow.....	12
3.4 Condensed Consolidated Statement of changes in equity .....	13

## 1. General information about the Company

### 1.1 Company details

<b>Company name:</b>	Agroliga Group PLC
<b>Seat:</b>	Nicosia, Cyprus
<b>Address:</b>	Boumpoulinas, 11, 1st floor, P.C. 1060, Nicosia, Cyprus
<b>Telephone:</b>	+38 (057) 766-50-70
<b>Fax:</b>	+38 (057) 766-50-70
<b>E-mail:</b>	info@agroliga.com.ua
<b>www:</b>	www.agroliga.com.ua

Source: Issuer

### 1.2 Company profile

Agroliga Group (“Group”) is Ukraine based company conducting food and agricultural business. The Group produces sunflower oil and different grains. The Group consists of twelve companies:

- Agroliga Group PLC – the holding company based in Cyprus;
- Agroliga operating in Ukraine. It conducts plant production;
- Mechnikovo operating in Ukraine. It specializes in milk cows breeding and plant production;
- Agrokom Novaya Vodolaga operating in Ukraine. It conducts sunflower oil production;
- Group of Companies Agroliga LLC– the holding company based in Ukraine.
- VostokAgroKontrakt operating in Ukraine. It conducts plant production;
- Mayak operating in Ukraine and conducts plant production. It was added to Group in August 2015.
- Agroliga-Trade LLC operating in Ukraine. It focuses on sales and trading services for other companies in the Group.
- LLC "AGL Energy" - is based in Ukraine, the main activity of the enterprise will be the production and sale of electricity.
- LLC Trading House Liga Trade operating in Ukraine. It focuses on sales and trading services for other companies in the Group.

### 1.3 Management Board

Oleksander Berdnyk - Chairman of the Board of Directors


Bizserve Investments Limited – Member of the Board of Directors

Bizserve Management Limited – Member of the Board of Directors

### 1.4 Shareholder structure

**Table 1 - The Shareholding structure of the Issuer, indicating shareholders holding at least 5% of the votes at the date of report (as of 14/11/2023)**

Stockholder	Number of shares	Number of votes at the general meeting	Participation in share capital	Participation in the total number of votes at the general meeting
Olexandr Berdnyk	640 750	640 750	41,66%	41,66%
Irina Poplavskaya	640 750	640 750	41,66%	41,66%
Free float	256 300	256 300	16,68%	16,68%
<b>ALL</b>	<b>1 537 800</b>	<b>1 537 800</b>	<b>100%</b>	<b>100%</b>



- Irina Poplavskaya
- Alexandr Berdnyk
- Others

## 1.5 Persons employed

There are 332 persons employed by Agroliga group as at 14/11/2023 (FTE, including all the Group's companies)

CATEGORY	14/11/2023
ADMINISTRATION	41
PRODUCTION EMPLOYEES	224
SUPPORT	67
<b>TOTAL</b>	<b>332</b>

## 2. Condensed Standalone Financial Statement for the 3Q2023

Tables below provide condensed interim financial statements of Agroliga Group PLC, in accordance with International Financial Reporting Standards for a 3Q 2023 (period ended 30 September 2023).

All data are presented in thousand EUR.

### 2.1 CONDENSED STANDALONE STATEMENT OF COMPREHENSIVE INCOME AND FINANCIAL POSITION

Statement of comprehensive income for the period began 01 January ended 30 September 2023			
		30 Sept. 2023	30 Sept. 2022
	Note	€000	€000
<b>Continuing operations</b>			
Sales revenue		6 923	2 273
Loan interest income		26	10
Cost of sales		(6 864)	(2 262)
Profit from investment activities		-	-
Income from change in fair value of agricultural		-	-
<b>Gross profit</b>		<b>85</b>	<b>21</b>
Other operating income/(expenses), net		-	3
Net foreign exchange loss		107	23
Selling and distribution costs		(135)	-
Administrative expenses		(29)	(44)
<b>Operating profit</b>		<b>28</b>	<b>2</b>
Financial income/(expenses), net		(8)	(3)
Exchange rate differences, net		-	-
<b>Profit before tax from continuing operations</b>		<b>20</b>	<b>(1)</b>
Income tax expense		-	-
<b>Profit for the year from continuing operations</b>		<b>20</b>	<b>(1)</b>
<b>Other comprehensive income for the year</b>			
Exchange difference on translating foreign operations		-	-
<b>Total other comprehensive income for the year</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive income for the year, net of tax</b>		<b>20</b>	<b>(1)</b>
<b>Total comprehensive income attributable to</b>			
Equity holders of the parent		20	(1)
Non-controlling interest		-	-

## Statement of comprehensive financial position for the period ended 30/09/2023 and 31/12/2022

<b>Statement of financial position</b>			
<b>for the period began 01 January ended 30 September 2023</b>			
		30 Sept. 2023	31 Dec 2022
		€ 000	€ 000
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment		-	-
Investments in subsidiaries		112	112
<b>Total non-current assets</b>		<u>112</u>	<u>112</u>
<b>Current assets</b>			
Current biological assets		0	0
Inventories		0	0
Loans receivable		4 188	4 675
Cash and cash equivalent		65	1 737
<b>Total current assets</b>		<u>4 253</u>	<u>6 412</u>
<b>Total assets</b>		<u>4 365</u>	<u>6 524</u>
<b>Equity and liabilities</b>			
Share capital		31	31
Share premium		953	953
Retained earnings (accumulated losses)		(488)	(507)
<b>Total equity</b>		<u>496</u>	<u>477</u>
<b>Current liabilities</b>			
Trade and other payables		3 869	6 047
<b>Total equity and liabilities</b>		<u>4 365</u>	<u>6 524</u>

## 2.2 CONDENSED STANDALONE STATEMENT OF CASHFLOW

Statement of cash flows for the period from 01.01.2023 to 30.09.2023

Statement of cash flows		30 Sept. 2023	30 Sept. 2022
for the period began 01 January ended 30 September 2023		€000	€000
Note		30 Sept. 2023	30 Sept. 2022
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
	<b>Profit before tax</b>	20	(1)
	Non-cash adjustment to reconcile profit before tax to net cash flows		
	Depreciation and impairment of property, plant and equipment	-	-
	Unrealised exchange loss/(profit)	(107)	(23)
	Interest income	(26)	(10)
		<u>(113)</u>	<u>(34)</u>
	<b>Changes in working capital:</b>		
	(Increase)/decrease trade and other receivables	487	(2 525)
	Increase/(decrease) in trade and other payables	(2 178)	2 521
	Interest received	26	10
	<b>Net cash flows from operating activities</b>	<u>(1 778)</u>	<u>(28)</u>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
	Loans granted	-	-
	<b>Net cash flows used in investing activities</b>	<u>-</u>	<u>-</u>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
	Unrealised exchange (loss)/profit	107	23
	Dividends paid	-	-
	<b>Net cash flows from/(used in) financing activities</b>	<u>107</u>	<u>23</u>
	Net increase in cash and cash equivalents	(1 671)	(5)
	<b>Cash and cash equivalents at beginning of the year</b>	1 737	29
	<b>Cash and cash equivalents at the end of the year</b>	<u>66</u>	<u>24</u>



## 2.3 CONDENSED STANDALONE STATEMENT FOR CHANGES IN EQUITY

Statement of changes in equity for the period from 01.01.2023 ended 30.09.2023

**Statement of changes in equity  
for the period began 01 January ended 30 September 2023**

	Share capital	Share premium	Retained earnings/ Accumulated losses	Total
<b>Balance at 31 December 2021/1 January 2022</b>	31	953	(479)	504
Net profit for the year	-	-	(29)	6
Total comprehensive income for the year, net of tax	-	-	(29)	6
Dividends paid			492	
<b>Balance at 31 December 2022</b>	31	953	(507)	476
Income for the period			20	20
Loss for the period	-	-	-	-
Total comprehensive income for the year, net of tax			20	20
Dividends paid			-	0
<b>Balance at 30 September 2023</b>	31	953	(488)	496

### 3. Condensed Financial Statements

Tables below provide data from condensed consolidated interim financial statements, prepared in accordance with International Accounting Standard for 3Q 2023 (period ended September 30, 2023). The condensed consolidated interim financial statements and comprehensive income position as well as consolidated statement for changes in equity present comparative data for 30.09.2023. All data are presented in thousand EUR.

#### 3.1 CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

**Condensed statement of profit or loss and other comprehensive income  
for the period from 01/01 to 30/09 of 2023 year (with comparative data)**

	01/01/2023 - 30/09/2023	01/01/2022 - 30/09/2022
	€000	€000
<b>Continuing operations</b>		
Sales revenue	29 400	33 039
Cost of sales	(25 767)	(26 453)
Income (expenses) from change in fair value of biological assets agricultural products	-	-
<b>Gross profit</b>	<b>3 633</b>	<b>6 586</b>
Administrative expenses	(493)	(553)
Distribution expenses	(1 862)	(2 002)
Other operating income/(expenses), net	6	998
<b>Operating profit</b>	<b>1 284</b>	<b>(3 194)</b>
Non-operational income/(expenses), net		
Financial income/(expenses), net	(656)	(732)
Exchange rate differences, net	27	(4 173)
<b>Profit before tax from continuing operations</b>	<b>655</b>	<b>124</b>
Income tax expense	(57)	(32)
<b>Profit for the year from continuing operations</b>	<b>598</b>	<b>92</b>
<b>Profit for the year attributable to</b>		
Equity holders of the parent	532	88
Non-controlling interest	66	4

## 3.2 CONDENSED STATEMENT OF FINANCIAL POSITION

**Condensed statement of financial position**
**as at 30 September 2023 and 31 December 2022 (with comparative data)**

	30 September, 2023	31 December, 2022
Assets	€000	€000
<b>Non-current assets</b>		
Property, plant and equipment	36 800	36 899
Right-of-use assets	745	737
Biological assets	26	13
Non-current loans receivable	-	
Deferred tax assets	24	23
<b>Total non-current assets</b>	<b>37 595</b>	<b>37 672</b>
<b>Current assets</b>		
Inventories and work in progress	13 482	11 456
Current biological assets	427	423
Trade and other receivables	16 338	18 330
Cash and cash equivalent	2 019	2 544
<b>Total current assets</b>	<b>32 266</b>	<b>32 753</b>
<b>Total assets</b>	<b>69 861</b>	<b>70 425</b>
<b>Equity and liabilities</b>		
Share capital	31	31
Share premium	953	953
Translation reserve	(15 497)	(14 985)
Retained earnings	46 651	46 119
Equity attributable to equity holders of the parent	32 138	32 118
Non-controlling interests	1 956	1 890
<b>Total equity</b>	<b>34 094</b>	<b>34 008</b>
<b>Non-current liabilities</b>		
Borrowings	2 201	4 415
Long-term portion of lease liabilities	691	684
Deferred tax liability	1 727	1 716
<b>Total non-current liabilities</b>	<b>4 619</b>	<b>6 815</b>
<b>Current liabilities</b>		
Trade and other payables	19 977	15 918

Interest-bearing loans and borrowings	513	507
Borrowings	10 634	13 155
Provisions	24	22
<b>Total current liabilities</b>	<b>31 148</b>	<b>29 602</b>
<b>Total equity and liabilities</b>	<b>69 861</b>	<b>70 425</b>

### 3.3 CONDENSED CONSOLIDATED STATEMENT OF CASHFLOW

#### Condensed statement of cash flows for the period ended 30.09.2023 with comparative data

##### Condensed statement of cash flows

for the period from 01/01 to 30/09 of 2023 year

€ '000	01/01/2023 - 30/09/2023	01/01/2022 - 30/09/2022
<b>Cash flows from operating activities</b>		
<b>Profit before tax</b>	<b>655</b>	<b>124</b>
Adjustments for:		
Depreciation of property, plant and equipment	1 228	1 409
Changes in the reserve of doubtful debts	-	-
Losses/gain on current assets sold	-	-
Exchange rate differences, net	(27)	4 173
Income from previously written off assets	-	-
Changes in deferred taxes	-	-
Income from change in fair value of biological assets	-	-
Exchange difference arising on the translation of assets on foreign currencies	-	-
Interest income	-	-
Interest expense	442	732
<b>Cash flows from operations before working capital changes</b>	<b>2 298</b>	<b>6 438</b>
Decrease/(increase) in inventories and work in progress	(2 026)	(1 447)
Decrease/(increase) in trade and other receivables	1 992	(5 590)
Decrease/(increase) in biological assets	(17)	102
(Decrease)/increase in trade and other payables	3 617	1 691
<b>Cash flows from operations</b>	<b>5 864</b>	<b>1 194</b>
Income tax paid	-	(32)
<b>Net cash flows from operating activities</b>	<b>5 864</b>	<b>1 162</b>
<b>Cash flows from investing activities</b>		
Payment for purchase of property, plant and equipment	(1 923)	(214)
Proceeds from disposal of property, plant and equipment	-	-
Loans granted	-	-
Interest received	-	-
<b>Net cash flows used in investing activities</b>	<b>(1 923)</b>	<b>(214)</b>

**Cash flows from financing activities**

Proceeds from issue of share capital	-	-
Proceeds of borrowings	11 222	1 400
Repayment of borrowings	(15 235)	(713)
Interest paid	(442)	(732)
Suspense account (pending correction of Depreciation, Minority interest and share capital)		
<b>Net cash flows (used in)/from financing activities</b>	<b>(4 455)</b>	<b>(45)</b>
Net increase (decrease) in cash and cash equivalents	<b>(514)</b>	<b>903</b>
Cash at beginning of the year/period	2 544	118
Effect of exchange rates fluctuations on cash	(11)	(9008)
<b>At end of the year/period</b>	<b>2 019</b>	<b>113</b>

**3.4 CONDENSED CONSOLIDATED STATEMENT FOR CHANGES IN EQUITY**
**Condensed consolidated statement for changes in equity for the period ended 30/09/2023**
**Condensed statement for changes in equity  
for the period from 01/01 to 30/09 of 2023  
year**

	Attributable to equity holders of the Company					Total
	Share capital	Share premium	Translation reserve	Retained earnings	Non-controlling interests	
	€000	€000	€000	€000	€000	
<b>Balance at 31 December 2021</b>	<b>31</b>	<b>953</b>	<b>(12 688)</b>	<b>25 189</b>	<b>681</b>	<b>14 166</b>
<b>Balance at 1 January 2022 as previously reported</b>	<b>31</b>	<b>953</b>	<b>(12 688)</b>	<b>25 189</b>	<b>681</b>	<b>14 166</b>
Net profit the period	-	-	-	769	37	806
Exchange difference on the translation	-	-	(2 297)	-	-	(2 297)
<b>Balance at 31 December 2022/1 January 2023</b>	<b>31</b>	<b>953</b>	<b>(14 985)</b>	<b>46 119</b>	<b>1 890</b>	<b>34 008</b>
Net profit the period	-	-	-	532	66	598
Exchange difference on the translation	-	-	(512)	-	-	(512)
<b>Balance at 30 September, 2023</b>	<b>31</b>	<b>953</b>	<b>(15 497)</b>	<b>46 651</b>	<b>1 956</b>	<b>34 094</b>

*Source: Issuer*

Statements were prepared according rules of IAS 34. There were no changes in accounting policy of the Group during period 01/01/23-30/09/23. More detailed Group's accounting policy is described in audited annual report of the Group.

Exchange rate effect was noted in Statement of financial position.

Aleksandr Berdnyk

Chairman of the Board of Directors



A handwritten signature in blue ink, appearing to read 'A. Berdnyk', is written over a horizontal line.